• Vaccine Name: RCN-rabies-G
• Target Pathogen: Rabies virus
• Target Disease: Rabies
• Vaccine Ontology ID: VO_0004693
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Glycoprotein G gene engineering:
  • Type: Recombinant vector construction
  • Description: A recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 1999).
  • Detailed Gene Information: Click Here.
• Vector: raccoon poxvirus vaccine vector
  • Vector name: raccoon poxvirus vaccine vector
  • VO vector ID: VO_0001048
• Preparation: Recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 2003).
• Immunization Route: Intramuscular injection (i.m.)

Cat Response

• Vaccination Protocol: The cats were vaccinated by the oral (PO), intranasal (IN), conjunctival (CO) or intranasal/conjunctival (IN/CO) route (dose: 10 plaque forming units or PFU) (Osorio et al., 2003).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Because of humanitarian concerns, we did not perform rabies virus challenge on these cats. However, RVNA titers of 1:5 (0.69 log10) or greater in humans have been correlated with vaccine protection (Smith et al., 1996). Thus, it is reasonable to surmise that the high RVNA titers observed in the immunized cats could provide protection against challenge (Osorio et al., 2003).
• Efficacy: The RVNA titers remained high when measured at six months post-vaccination, demonstrating that the recombinant vaccine administered via these routes is very efficient at inducing long-lasting immunity (Osorio et al., 2003).